Alaunos Therapeutics regains Nasdaq minimum bid price compliance; panel monitor for one year

Alaunos Therapeutics, Inc.

Nasdaq notified Alaunos on Feb 16, 2024 that it has regained compliance with the $1.00 bid price requirement.
All applicable criteria for continued listing are satisfied; the listing matter is closed.
Subject to mandatory panel monitor under Nasdaq Rule 5815(d)(4)(B) through Feb 16, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.